Metoclopramide Amdipharm Uk

Metoclopramide, the active ingredient in Metoclopramide Amdipharm UK, is a dopamine D2 receptor antagonist presented as an injectable solution for intravenous use. It is employed to treat nausea and vomiting, including postoperative nausea, gastroparesis, and migraine‑associated nausea in adult patients.

GNH USA supplies Metoclopramide Amdipharm UK as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide is an antiemetic that acts on the chemoreceptor trigger zone and gastrointestinal tract.

- Nausea and vomiting: reduces frequency and severity of acute episodes. - Postoperative nausea and vomiting: prevents and treats nausea after surgical procedures. - Gastroparesis: enhances gastric emptying and alleviates related symptoms. - Migraine‑associated nausea: alleviates nausea accompanying migraine attacks.

Metoclopramide may cause a range of adverse reactions.

Common Side Effects: - Drowsiness - Fatigue - Restlessness - Diarrhea

Serious or Rare Side Effects: - Extrapyramidal reactions (e.g., dystonia) - Neuroleptic malignant syndrome - Tardive dyskinesia - Seizures

Metoclopramide requires careful use in several clinical situations.

- Parkinson's disease: avoid because dopamine antagonism may worsen symptoms. - Depression or suicidal thoughts: monitor closely for mood changes. - Renal or hepatic impairment: dose adjustment may be necessary. - Known hypersensitivity: discontinue if allergic reaction occurs. - Elderly patients: increased risk of extrapyramidal symptoms, use with caution. - Store at room temperature: keep in original container, protect from light and moisture.

Metoclopramide can interact with several drug classes.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): additive central nervous system effects. - MAO inhibitors: risk of hypertensive crisis. - CNS depressants (e.g., opioids, benzodiazepines): enhanced sedation. - Anticholinergics: may diminish prokinetic activity.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., codeine): altered metabolism. - SSRIs (e.g., sertraline): increased risk of serotonin syndrome. - Digoxin: possible increase in serum concentration.